Marinosolv®: Efficacy clinically validated
The clinical phase III for the flagship product Budesolv, a nose spray to treat allergic rhinitis, was carried out in the first quarter and successfully completed in April 2019. Marinomed achieved all study objectives. The advantages of the Marinosolv® platform are thereby clinically validated.
Carragelose®: Targeting new markets
The products of the Carragelose® platform have a proven global track record as the first causal therapy for colds and flu infections. At the present time revenues are generated with 14 worldwide partners and six products in more than 40 countries. In the first quarter 2019 the focus lay on the preparation for entry into new markets as well as launches of additional products in existing markets.
Results shaped by investments in growth
The successful IPO and high investments in the future growth trajectory were reflected in the financial performance of the period. Total assets increased from EUR 5.26 million as of December 31, 2018 to EUR 20.93 million as of March 31, 2019. Cash and cash equivalents increased to EUR 17.84 million in the first quarter 2019 (12/2018: EUR 1.72 million).
Unlike conventional biotechnology companies, Marinomed is already generating revenues from the sale of products from its Carragelose® platform. Positive sales performance in several markets in the first quarter 2019 could not compensate for the temporarily weaker demand in two core markets, which profited from product launches in the prior year period. Revenues stood at EUR 0.75 million, after strong EUR 0.92 million in the first quarter 2018. The operating result (EBIT) was negative according to plan and amounted to EUR -2.63 million, impacted by higher R&D expenses and one-time costs in connection with the IPO (1-3/2018: EUR -1.05 million).
Positive Outlook 2019
With the Marinosolv® platform Marinomed targets the USD 5 billion global market for cortisone-based allergic rhinitis treatment. Next steps include the preparation of the regulatory submission of Budesolv, which is set to take place in 2020, as well as the start of the clinical phase II for Tacrosolv, a product to treat inflammatory ocular disorders, in the second half of 2019. Marinomed sees further substantial growth potential in the pharmaceutical market for OTC products for Carragelose®-based products against a backdrop of what remains intense competitive pressure.
Marinomed expects continuing positive performance for orders and sales in 2019. However, the high research & development expenses mean that it expects operating losses for the fiscal year 2019.
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange since February 1, 2019. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Further information is available at: www.marinomed.com.
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements speak only as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statement contained in this press release whether as a result of new information, future developments or otherwise.